IBA signs contract to install proton therapy center in Italy

Proteus^®ONE contract worth between EUR 35 and 40 million to IBA

Louvain-La-Neuve, Belgium, 28 May 2019 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract and received the downpayment for the delivery of a Proteus^®ONE solution with the European Institute of Oncology (IEO) in Milan, Italy.

The contract includes a long-term operation and maintenance agreement. The typical end-user price for a Proteus^®ONE* solution with a maintenance contract is between EUR 35 and 40 million. IBA will begin to recognize revenue for the contract in the 2019 financial year.

IBA was selected as the preferred partner for this project following a comprehensive vendor selection process. The hospital expects to start treating patients in 2022.

With a 48% market share in compact systems, IBA is further strengthening its undisputed global leadership position.

Olivier Legrain, Chief Executive Officer of IBA, commented: “We are delighted to collaborate with the European Institute of Oncology to build its proton therapy center. IEO is a leader in research and cancer care, both in Italy and Europe. The IEO Advanced Radiotherapy Center in particular is ranked amongst the top five centers in Europe for technology, equipment and number of patients treated. This new collaboration strengthens our world leading position in proton therapy and demonstrates IBA’s superior product offering in the market.”

Mr. Mauro Melis, Chief Executive Officer of IEO, commented: “We are glad to partner with IBA, one of the world’s leading proton therapy systems providers. With this new proton therapy center, we will contribute to the development of international studies on the clinical use of proton therapy, and at the same time we will expand our state-of-the-art offering of cancer therapies. With its open gantry and advanced technologies, IBA’s Proteus^®ONE solution is the right choice to provide greater access to proton therapy in Italy.”

Prof. Roberto Orecchia, Scientific Director of IEO, said: “Proton therapy is a superior form of radiotherapy and nowadays represents a new and better treatment choice for many cancer forms. However, there is still a lot we have to discover about proton therapy. An important aspect of entering into a partnership with IBA is to become part of its large proton therapy user community and to participate in its research collaborations on new technologies such as motion management, Proton Arc Therapy and Proton Flash Therapy. These novel techniques have the potential to change the landscape of radiotherapy and patient cancer care.”

***ENDS***

About Proteus^®ONE

Proteus^®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus^®ONE is smaller, more affordable, easier to install and to operate, making this advanced radiation therapy modality available to more institutions and patients worldwide.

* Proteus^®ONE is the brand name of Proteus^®235.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1400 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

About IEO (European Institute of Oncology)

The European Institute of Oncology (Istituto Europeo di Oncologia – IEO) strives for excellence in cancer prevention, early diagnosis and effective treatment. We aim to achieve this through clinical and scientific research development, organisational and management innovation, with a constant focus on the quality of the service provided to the patients.

The IEO staff are driven and inspired by the following values and principles:

• Patient focus
• Continuous healthcare quality improvement
• Service excellence
• Multidisciplinary approach to clinical care
• Participation in trial research and rapid transfer of results to the patients
• Enhancing the value of human resources
• European spirit and openness to international collaborations

More information can be found at:

For further information, please contact:

IBA

Soumya Chandramouli

Chief Financial Officer

Thomas Ralet

Head of Corporate Communication

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Angela Gray, Lizzie Seeley

+44 (0) 20 3709 5700

Attachment